Open-label Extension to Protocol 1042-0600

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

September 30, 2013

Conditions
Epilepsies, Partial
Interventions
DRUG

ganaxolone

liquid suspension dosed tid

Trial Locations (25)

12208

Neurosciences Institute at Albany Medical Center, Albany

13210

SUNY Upstate Medical University, Syracuse

19063

Riddle Health Care Center for Neuroscience, Media

19107

Thomas Jefferson University, Philadelphia

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

23298

Virginia Commonwealth University, Richmond

30322

Emory HealthCare, Atlanta

34232

Intercoastal Neurology, Sarasota

37232

Vanderbilt University Medical Center, Nashville

40536

University of Kentucky, Dept. of Neurology, Lexington

43210

Ohio State University Medical Center, Columbus

48202

2799 West Grand blvd. CFP 071, Detroit

52242

University of Iowa Hospitals and Clinics, Iowa City

62702

Southern Illinois University Medical Center, Springfield

63017

Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield

72205

Arkansas Epilepsy Program, Little Rock

75230

Neurological Clinic of Texas, P.A., Dallas

85013

Barrow Neurological Institute, Phoenix

90033

University of Southern California Adult Comprehensive Epilepsy Center, Los Angeles

95817

University of California-Davis, Sacramento

35294-0021

University of Alabama, Birmingham

80010-0045

Anchutz Outpatient Pavillion Neurosciences Clinic/ University of Colorado Hospital, Aurora

06520

Yale University School of Medicine, New Haven

32610-0236

University of Florida McKnight Brain Institute, Gainesville

55102-2383

Minnesota Epilepsy Group, PA, Saint Paul

Sponsors
All Listed Sponsors
lead

Marinus Pharmaceuticals

INDUSTRY

NCT00512317 - Open-label Extension to Protocol 1042-0600 | Biotech Hunter | Biotech Hunter